Public Health England HCV Resistance Group: overview and consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection

Journal article

The treatment of hepatitis C virus (HCV) infection has been revolutionised by the advent of oral, well-tolerated, direct acting antiviral therapies (DAA), with high cure rates. However, in some scenarios, HCV resistance to antiviral therapies may have an impact on treatment success. Public Health England's HCV Resistance Group was established to support clinicians treating people with HCV, where the issue of resistance may be a factor in clinical decision-making, and this review includes the Group's current recommendations on the use of HCV resistance testing. The authors describe the principles behind and approach to HCV resistance testing and consider evidence from in vitro studies, clinical trials and real world cohorts on the impact of HCV resistance on treatment outcomes for particular DAA regimens. Five scenarios are identified in the UK and similar settings, where, in the Group's opinion, resistance testing should be performed.

Authors: Bradshaw, D; Mbisa, J; Geretti, A; Healy, B; Cooke, G

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Elsevier
• Journal: Journal of Infection
• Volume: 79
• Issue: 6
• Pages: 503-512
• Publication date: 2019-10-16
• Acceptance date: 2019-10-13
• DOI: 10.1016/j.jinf.2019.10.007
• EISSN: 1532-2742
• ISSN: 0163-4453
• Pmid: 31629015
• Language: English
• Keywords: sequencing; hepatitis C virus; resistance testing; direct acting antivirals